← Back to headlines
Merck Reports Positive Phase 3 Results for Oral PCSK9 Inhibitor
Merck (MRK) has announced strong Phase 3 clinical trial results for its oral PCSK9 inhibitor, a drug designed to lower cholesterol.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Hawaii Doctor Convicted of Attempted Murder on Cliffside Hike
22m ago
Boil Water Notice Issued for New Plymouth Areas Due to E. coli
29m ago
Five Children Die of Suspected Encephalitis in Rajasthan, Health Department on Alert
47m ago
Hong Kong Halts Sales of French Oysters Over Gastroenteritis Link
50m ago